coronaviru
diseas
global
health
pandem
emerg
diseas
name
coronaviru
diseas
present
symptom
rang
mild
sever
fatal
respiratori
condit
epidemi
emerg
spread
rapidli
worldwid
confirm
case
around
relat
death
report
global
clinic
present
might
rang
mild
sever
lower
respiratori
tract
symptom
result
lifethreaten
complic
acut
respiratori
distress
syndrom
ard
two
seriou
coronavirusrel
outbreak
occur
past
two
decad
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
sinc
shown
analog
mechan
sar
exist
antivir
drug
use
past
epidemi
ribavirin
interferon
lopinavirritonavir
primarili
propos
drug
reposit
list
sever
benefit
drug
alreadi
avail
market
therefor
promptli
access
safeti
profil
dosag
alreadi
known
base
promis
preliminari
data
wide
rang
virus
chloroquin
sulfat
cq
drug
use
long
time
prophylaxi
malaria
recommend
dosag
mg
bid
treatment
choic
hydroxychloroquin
hcq
sulfat
first
synthes
hydroxyl
deriv
cq
hcq
shown
less
toxic
profil
cq
anim
model
crucial
avail
worldwid
sinc
use
treat
autoimmun
diseas
rheumatoid
arthriti
system
lupu
erythematosu
sinc
two
molecul
share
similar
structur
immunomodul
function
hcq
also
recommend
includ
therapeut
armamentarium
treat
infect
dosag
mg
bid
thu
proteas
inhibitor
combin
lopinavirritonaviralreadi
approv
treatment
human
immunodefici
viru
hiv
type
associ
either
cq
hcq
repres
standard
care
symptomat
patient
far
caution
prescrib
cqhcq
treatment
patient
dehydrogenas
defici
gener
observ
due
prohemolyt
effect
molecul
dehydrogenas
defici
common
worldwid
distribut
hereditari
red
cell
enzymat
defect
preval
million
affect
subject
although
defici
benign
haematolog
disord
acut
haemolyt
crisi
trigger
exposit
oxid
agent
fava
bean
drug
infect
might
common
lifethreaten
clinic
present
caucasian
man
admit
ed
fatigu
dyspnea
dizzi
fever
signific
element
present
patient
histori
particular
neurolog
disord
haemolyt
anemia
recent
introduct
new
drug
suffer
ischem
cardiomyopathi
recent
stent
interventricular
coronari
arteri
physic
examin
reveal
signific
reduct
peripher
satur
ambient
air
chest
xray
document
presenc
bilater
interstiti
pneumonia
laboratori
test
show
normal
hemoglobin
hb
gdl
mild
reduct
platelet
count
observ
affect
patient
presenc
infect
document
rtpcr
analysi
nosethroat
swab
patient
hospit
unit
treatment
lopinavir
plu
hcq
oxygen
support
stare
hour
hospit
observ
acut
drop
hb
figur
associ
appear
hemoglobinuria
chang
leukocyt
count
observ
reactiv
protein
c
increas
renal
test
normal
ldh
level
undetermin
due
intravascular
haemolysi
fig
direct
indirect
antiglobulin
test
neg
exclud
immunemedi
acut
haemolysi
peripher
blood
smear
show
anisopoikilocytosi
reticulocyt
larg
roundshap
cell
ii
hemighost
cell
character
pack
hemoglobin
one
side
larg
vacuum
cytoplasm
iii
microspherocyt
iv
schistocyt
suggest
blister
process
figur
hcq
withdrawn
patient
transfus
trigger
acut
haemolyt
crisi
hcq
patient
suspect
defici
affect
lung
diseas
patient
might
affect
mediterannean
variant
defici
sensit
prooxid
drug
compar
african
variant
conclus
data
avail
possibl
prohemolyt
impact
cqhcq
patient
defici
emerg
believ
import
warn
possibl
hemolyt
effect
cqhcq
patient
defici
thu
acut
drop
hb
level
earli
day
cqhcq
treatment
symptomat
patient
consid
suspici
possibl
defici
cqhcq
discontinu
hemolysi
gener
selflimit
cqhcq
withdrawn
fund
studi
author
noth
disclos
would
like
thank
prof
md
cappellini
prof
l
luzzatto
fruit
discuss
